Evaluating Atrial Fibrosis as a Predictor for Post-operative Atrial Fibrillation in Cardiac Surgery Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the relationship between baseline atrial fibrosis and the incidence of post-operative atrial fibrillation (POAF) in patients undergoing cardiac surgery. A total of 50 patients aged 40 and older, with no prior history of atrial arrhythmias, will undergo cardiac magnetic resonance imaging (MRI) to determine their Utah fibrosis stage. Following their surgeries, the incidence of atrial arrhythmias, in-hospital mortality, length of stay, and complication rates will be monitored and compared across different fibrosis stages. The study seeks to provide insights into how atrial fibrosis may influence surgical outcomes and healthcare costs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients age 40 years of age or older
* Patients with no history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) scheduled to undergo cardiac surgery (These surgeries include but are not limited to coronary artery bypass graft (CABG), valvular repair/reconstruction, aneurysm repair, and insertion of pacemaker).

Exclusion Criteria:

* Patients with a history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia)
* Patients with a history of cardiac or open chest surgery
* Patients with a history of catheter ablation
* Patients under the age of 40
* Patients with left ventricular assist device (LVAD) or scheduled to have LVAD implanted
* Patients who have previously undergone extracorporeal membrane oxygenation (ECMO)
* Patients who have undergone or will undergo heart transplantation
* Patients with any health related Late Gadolinium Enhancement (LGE)-MRI contraindications (including previous allergic reaction to gadolinium, pacemakers, defibrillators, other devices/implants contraindicated for MRI)
* Acute or chronic severe renal disease with a low glomerular filtration rate (GFR), \<30 mL per minute per 1.73 m2 will be excluded from the trial. (A creatinine measurement should be available within the last 6 months. If not, a creatinine blood test will be drawn to assess for renal function before the MRI acquisition).
* Patients weighing \> 300 lbs. (MRI image quality decreases due to increased body mass index)
* Patients currently pregnant or breastfeeding, or plan to become pregnant during the study period
* Patients with cognitive impairment preventing them from giving informed consent will be excluded from the study
* Patients who cannot read, speak, and/or understand English

Where it's running

• Lakeview Hospital
  Covington, Louisiana, United States Recruiting
• East Jefferson General Hospital
  New Orleans, Louisiana, United States Recruiting
• Washington University Barnes-Jewish Hospital
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Jamil Borgi, MD — Tulane University
• Study coordinator: Yara Menassa, MD
• Email: ymenassa@tulane.edu
• Phone: 504-316-2003

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using the VERAFEYE imaging and navigation system to guide catheter ablation for atrial arrhythmias

  This study will try the VERAFEYE imaging and guidance system during catheter ablation in adults with atrial flutter or atrial fibrillation to see if it integrates well with standard procedures.

  Recruiting LUMA Vision Ltd. · Split · NCT07271238

• Anatomical navigation to guide catheter ablation for atrial fibrillation and flutter

  This trial will test whether the VERAFEYE Anatomical Guidance System helps doctors guide catheter ablation in adults with atrial fibrillation or atrial flutter.

  Recruiting at 2 sites LUMA Vision Ltd. · Split and 3 other locations · NCT07210151

• Long-term outcomes for patients with cardiac arrhythmias

  This study looks at how well treatments for heart rhythm problems work over time and what factors might affect their success for patients with conditions like atrial fibrillation and ventricular tachycardia.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT05521451

• Volta AI software in real-world AF ablation

  A real-world observational study will test the latest Volta AF-Xplorer II AI software during atrial fibrillation ablation to see how safe and effective it is over 24 months.

  Recruiting Volta Medical · Marseille and 2 other locations · NCT07621055

• HeartBeam ECG Registry: See How Heartbeat Patterns Look Across People

  This registry tests HeartBeam ECG recordings in real-world patients to build a de-identified database for research.

  Recruiting HeartBeam, Inc. · Pittsburgh, Pennsylvania · NCT07501299

• AV node ablation with left bundle branch area pacing versus right ventricular pacing for atrial fibrillation with preserved heart function

  This test checks whether left bundle branch area (LBBA) pacing instead of right ventricular (RV) pacing after AV node ablation better preserves heart function in adults with symptomatic atrial fibrillation and normal ejection fraction.

  Recruiting St. Josefs-Hospital Wiesbaden GmbH · Hagen and 1 other locations · NCT07428967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.